Non-coding RNAs to Treat Vascular Smooth Muscle Cell Dysfunction

Simon D. Brown; Eftychia Klimi; Wilfried A. M. Bakker; Abdelaziz Beqqali; Andrew H. Baker

doi:10.1111/bph.16409

Non-coding RNAs to Treat Vascular Smooth Muscle Cell Dysfunction

Simon D. Brown, Eftychia Klimi, Wilfried A. M. Bakker, Abdelaziz Beqqali, Andrew H. Baker^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Abstract / Description of output

Vascular smooth muscle cell (vSMC) dysfunction is a critical contributor to cardiovascular diseases, including atherosclerosis, restenosis, and vein graft failure. Recent advances have unveiled a fascinating breadth of non-coding RNAs (ncRNAs) that play a pivotal role in regulating vSMC function. This review aims to provide an in-depth analysis of the mechanisms
underlying vSMC dysfunction and the therapeutic potential of various ncRNAs in mitigating this dysfunction, either preventing or reversing it. We explore the intricate interplay of microRNAs, long-non-coding RNAs and circular RNAs, shedding light on their roles in regulating key signalling pathways associated with vSMC dysfunction. Moreover, we discuss the prospects and challenges associated with developing ncRNA based therapies for this prevalent cardiovascular pathology.

Original language	English
Journal	British Journal of Pharmacology
Early online date	21 May 2024
DOIs	https://doi.org/10.1111/bph.16409
Publication status	E-pub ahead of print - 21 May 2024

Access to Document

10.1111/bph.16409Licence: Creative Commons: Attribution (CC-BY)

Final Manuscript APRIL2024Accepted author manuscript, 857 KBLicence: Creative Commons: Attribution (CC-BY)
British J Pharmacology - 2024 - Brown - Non‐coding RNAs to treat vascular smooth muscle cell dysfunctionFinal published version, 4.16 MBLicence: Creative Commons: Attribution (CC-BY)

Cite this

@article{8fdd699ca6574b2c95ba9ddea206fffb,

title = "Non-coding RNAs to Treat Vascular Smooth Muscle Cell Dysfunction",

abstract = "Vascular smooth muscle cell (vSMC) dysfunction is a critical contributor to cardiovascular diseases, including atherosclerosis, restenosis, and vein graft failure. Recent advances have unveiled a fascinating breadth of non-coding RNAs (ncRNAs) that play a pivotal role in regulating vSMC function. This review aims to provide an in-depth analysis of the mechanismsunderlying vSMC dysfunction and the therapeutic potential of various ncRNAs in mitigating this dysfunction, either preventing or reversing it. We explore the intricate interplay of microRNAs, long-non-coding RNAs and circular RNAs, shedding light on their roles in regulating key signalling pathways associated with vSMC dysfunction. Moreover, we discuss the prospects and challenges associated with developing ncRNA based therapies for this prevalent cardiovascular pathology.",

author = "Brown, {Simon D.} and Eftychia Klimi and Bakker, {Wilfried A. M.} and Abdelaziz Beqqali and Baker, {Andrew H.}",

year = "2024",

month = may,

day = "21",

doi = "10.1111/bph.16409",

language = "English",

journal = "British Journal of Pharmacology",

issn = "0007-1188",

publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Non-coding RNAs to Treat Vascular Smooth Muscle Cell Dysfunction

AU - Brown, Simon D.

AU - Klimi, Eftychia

AU - Bakker, Wilfried A. M.

AU - Beqqali, Abdelaziz

AU - Baker, Andrew H.

PY - 2024/5/21

Y1 - 2024/5/21

N2 - Vascular smooth muscle cell (vSMC) dysfunction is a critical contributor to cardiovascular diseases, including atherosclerosis, restenosis, and vein graft failure. Recent advances have unveiled a fascinating breadth of non-coding RNAs (ncRNAs) that play a pivotal role in regulating vSMC function. This review aims to provide an in-depth analysis of the mechanismsunderlying vSMC dysfunction and the therapeutic potential of various ncRNAs in mitigating this dysfunction, either preventing or reversing it. We explore the intricate interplay of microRNAs, long-non-coding RNAs and circular RNAs, shedding light on their roles in regulating key signalling pathways associated with vSMC dysfunction. Moreover, we discuss the prospects and challenges associated with developing ncRNA based therapies for this prevalent cardiovascular pathology.

AB - Vascular smooth muscle cell (vSMC) dysfunction is a critical contributor to cardiovascular diseases, including atherosclerosis, restenosis, and vein graft failure. Recent advances have unveiled a fascinating breadth of non-coding RNAs (ncRNAs) that play a pivotal role in regulating vSMC function. This review aims to provide an in-depth analysis of the mechanismsunderlying vSMC dysfunction and the therapeutic potential of various ncRNAs in mitigating this dysfunction, either preventing or reversing it. We explore the intricate interplay of microRNAs, long-non-coding RNAs and circular RNAs, shedding light on their roles in regulating key signalling pathways associated with vSMC dysfunction. Moreover, we discuss the prospects and challenges associated with developing ncRNA based therapies for this prevalent cardiovascular pathology.

U2 - 10.1111/bph.16409

DO - 10.1111/bph.16409

M3 - Article

SN - 0007-1188

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

ER -

Non-coding RNAs to Treat Vascular Smooth Muscle Cell Dysfunction

Abstract / Description of output

Access to Document

Fingerprint

Cite this